Steatotic liver disease and HIV: an agenda for 2030.

Pericàs, Juan M; Arora, Anish K; Riebensahm, Carlotta; Jiménez-Masip, Alba; Ramírez Mena, Adrià; White, Trenton M; Dedes, Nikos; Guaraldi, Giovanni; Berzigotti, Annalisa; Wandeler, Gilles; Bansal, Meena B; Navarro, Jordi; Lazarus, Jeffrey V (2024). Steatotic liver disease and HIV: an agenda for 2030. The Lancet HIV, 11(8), e561-e566. Elsevier 10.1016/S2352-3018(24)00097-3

Text 1-s2.0-S2352301824000973-main.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (520kB)

People living with HIV are particularly susceptible to developing metabolic disorders, including metabolic dysfunction-associated steatotic liver disease and other forms of SLD. However, people living with HIV have been historically excluded from clinical trials and large cohort studies of SLD. Therefore, our understanding of the risk factors and natural history of SLD in this population is poor. Moreover, relevant knowledge gaps on the epidemiology and barriers for adequate health care, such as stigma, hamper adequate responses to the ongoing HIV and SLD syndemic. This Viewpoint provides a comprehensive perspective on how to tackle SLD in people living with HIV by examining the role of social determinants of health in the development of liver disease and metabolic syndrome comorbidities among this population, emphasising the importance of prioritising SLD management, summarising the most urgent needs in the field, and offering recommendations for advancing research to fill key data gaps and protect liver health of people living with HIV.

Interest & Impact

Downloads

1 since deposited on 09 Jul 2024
1 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item